NFL

New Blood Biomarker Technology May Help to Predict MS Activity

Simoa, a technology that detects relevant molecules in samples with up to 1,000 times greater sensitivity than conventional methods, has helped to advance research into a blood biomarker expected to predict future disease activity in multiple sclerosis (MS) patients. Specifically, Quanterix‘s ultra-sensitive technology allowed an international team…

#ACTRIMS2022 ā€“ Blood NfL Levels May Help Quantify Relapse Severity

Measuring levels of the neurofilament light chain (NfL) protein in blood may be a way to “quantify” relapse severity and predict future disability in people with relapsing-remitting multiple sclerosis (RRMS). “Higher [blood] NfL levels during periods of active inflammation predicted more [brain] atrophy,” researchers wrote in an abstract titled…

sNfL Levels Linked to Relapse-free Disability Progression, Move to SPMS

Measuring levels of the protein serum neurofilament light chain (NfL)Ā can help to identify people with relapsing-remitting multiple sclerosis (RRMS) at higher risk of relapse-free disability progression or conversion to secondary-progressive disease, according to a study from Germany. The study, “NfL predicts relapse-free progression in a longitudinal…

NfL Mirrors Some Life Quality Aspects Felt by Patients, More Work Needed

Levels of neurofilament light (NfL), a protein marker of neuronal damage, appear to capture some aspects of patientā€perceived physical and functional abilities withĀ multiple sclerosis (MS), as well as theirĀ utilization of select healthcare services, a real-world study suggests. Its researchers, however, stress that more work is needed before NfL levels…

Blood NfL Potential Marker of MS Therapies’ Effectiveness, Study Suggests

Starting treatment with aĀ disease-modifying therapy (DMT) reduces blood levels of neurofilament light chain (NfL) ā€” a potential biomarker of disease progression and activity ā€” to varying degrees depending on the therapy used, according to a large real-world study of patients with relapsing-remitting multiple sclerosis (RRMS). The findings support…

Profiling Inflammatory Markers in Cerebrospinal Fluid of Importance in Active MS, Case Study Finds

Careful profiling of inflammatory markers in cerebrospinal fluid (CSF) of multiple sclerosis patients, coupled with standard exams and scans, helps in understanding disease evolution and treatment response, a case report suggests. It followed aĀ relapsing-remitting multiple sclerosis (RRMS) patient whose inflammatory markers in the CSF remained high over time, and…

Michiganā€™s Memorial Healthcare First in US to Test NfL in MS Patients

Memorial Healthcare Institute for Neurosciences and Multiple SclerosisĀ announced it will become the first U.S. hospital to test a nerve cell-derived component known as neurofilament light chain (NfL) in multiple sclerosis (MS) patients. Led by the Owosso, Michigan, hospitalā€™s chief of neurology and MS director, Rany Aburashed, DO,…